Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. by Sattentau, Q, Zolla-Pazner, S, Poignard, P

Antibody neutralization of HIV-1. by Poignard, P, Klasse, P, Sattentau, Q

Human and simian immunodeficiency viruses: virus-receptor interactions. by Signoret, N, Poignard, P, Blanc, D, Sattentau, Q

Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation. by Poignard, P, Fouts, T, Naniche, D, Moore, J, Sattentau, Q

Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding. by Sattentau, Q, Moore, J, Vignaux, F, Traincard, F, Poignard, P

Erratum to "Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design". by Parren, P, Gauduin, M, Koup, R, Poignard, P, Sattentau, Q, Fisicaro, P, Burton, DR

The activity of a potent neutralizing human antibody against primary isolates in vivo by Burton, DR, Parren, P, Poignard, P, Mosier, D, Gauduin, M, Koup, R, Sattentau, Q

Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design. by Parren, P, Gauduin, M, Koup, R, Poignard, P, Fisicaro, P, Burton, DR, Sattentau, Q

Mechanisms of escape from the PGT128 family of anti-HIV broadly neutralizing antibodies by Krumm, S, Mohammed, H, Le, K, Crispin, M, Wrin, T, Poignard, P, Burton, D, Doores, K

Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design (vol 57, pg 105, 1997) by Parren, P, Gauduin, M, Koup, R, Poignard, P, Sattentau, Q, Fisicaro, P, Burton, DR

Antibody neutralization of HIV-1 and the potential for vaccine design. by Sattentau, Q, Moulard, M, Brivet, B, Botto, F, Guillemot, J, Mondor, I, Poignard, P, Ugolini, S

Development of Broadly Neutralizing Antibody Responses in a Large Sub-Sahara African HIV Primary Infection Cohort by Landais, E, Simek, M, Price, M, Cormier, E, Gilmour, J, Fast, P, Allen, S, Kilembe, W, Karita, E, Lakhi, S, Inambao, M, Kamali, A, Sanders, E, Anzala, O, Wrin, T, Poignard, P

Recognition and penetration of the HIV-1 Env glycan shield by potent broadly neutralizing antibodies by Julien J, Kong L, Pejchal R, Khayat R, Lee J, Stanfield RS, Walker LM, Doores KJ, Folkowska E, Poignard P, Depetris R, Sanders RW, Koff WC, Moore JP, Ward AB, Burton DR, Wilson IA

Identification of a clade A HIV envelope immunogen from Protocol G that elicits neutralizing antibodies to tier 2 viruses by Hoffenberg S, Pond S, Carpov A, Wagner D, Wilson A, Powell R, Lindsay R, Arendt H, DeStefano J, Poignard P, Simek M, Fling S, Phogat S, Labranche C, Montefiori D, Burton D, Parks C, King C, Koff W, Caulfield M

African Early Infection Cohort as a Platform for Vaccine Discovery: The IAVI Protocol C Experience. by Gilmour, J, Kamali, A, Karita, E, Kilembe, W, Sanders, E, Anzala, O, Allen, S, Edward, V, Priddy, F, Price, M, Macharia, G, Baalwa, J, Crotty, S, Denny, T, Landais, E, Borrow, P, Tang, J, Busch, M, Prince, J, Claiborne, D, Poignard, P, Fast, P, Hunter, E

Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort. by Landais, E, Huang, X, Havenar-Daughton, C, Murrell, B, Price, M, Wickramasinghe, L, Ramos, A, Bian, C, Simek, M, Allen, S, Karita, E, Kilembe, W, Lakhi, S, Inambao, M, Kamali, A, Sanders, E, Anzala, O, Edward, V, Bekker, L, Tang, J, Gilmour, J, Kosakovsky-Pond, S, Phung, P, Wrin, T, Crotty, S, Godzik, A, Poignard, P